CN111225681A - 方法 - Google Patents

方法 Download PDF

Info

Publication number
CN111225681A
CN111225681A CN201880065375.2A CN201880065375A CN111225681A CN 111225681 A CN111225681 A CN 111225681A CN 201880065375 A CN201880065375 A CN 201880065375A CN 111225681 A CN111225681 A CN 111225681A
Authority
CN
China
Prior art keywords
peptide
subject
disease
seq
myelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880065375.2A
Other languages
English (en)
Chinese (zh)
Inventor
K.马丁
L.詹森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baimingxinkang Biotechnology Zhejiang Co ltd
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713037.8A external-priority patent/GB201713037D0/en
Priority claimed from GBGB1713035.2A external-priority patent/GB201713035D0/en
Priority claimed from GBGB1713036.0A external-priority patent/GB201713036D0/en
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of CN111225681A publication Critical patent/CN111225681A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880065375.2A 2017-08-14 2018-08-14 方法 Pending CN111225681A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1713037.8A GB201713037D0 (en) 2017-08-14 2017-08-14 Method
GBGB1713035.2A GB201713035D0 (en) 2017-08-14 2017-08-14 Method
GB1713035.2 2017-08-14
GB1713037.8 2017-08-14
GB1713036.0 2017-08-14
GBGB1713036.0A GB201713036D0 (en) 2017-08-14 2017-08-14 Method
PCT/GB2018/052304 WO2019034862A1 (en) 2017-08-14 2018-08-14 Method

Publications (1)

Publication Number Publication Date
CN111225681A true CN111225681A (zh) 2020-06-02

Family

ID=63294371

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880065375.2A Pending CN111225681A (zh) 2017-08-14 2018-08-14 方法

Country Status (8)

Country Link
US (1) US20210093695A1 (enExample)
EP (1) EP3668535A1 (enExample)
JP (1) JP7419229B2 (enExample)
CN (1) CN111225681A (enExample)
AU (2) AU2018316662A1 (enExample)
CA (1) CA3072867A1 (enExample)
WO (1) WO2019034862A1 (enExample)
ZA (1) ZA202000882B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111983241A (zh) * 2020-09-04 2020-11-24 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023100758A1 (enExample) * 2021-11-30 2023-06-08

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CN101848725A (zh) * 2007-10-31 2010-09-29 艾匹托普技术(布里斯托尔)有限公司 组合物
CN105102477A (zh) * 2013-01-15 2015-11-25 艾匹托普国际股份有限公司 肽
CN105121463A (zh) * 2013-01-15 2015-12-02 艾匹托普国际股份有限公司 肽

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3268382B1 (en) * 2015-03-09 2021-05-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CN101848725A (zh) * 2007-10-31 2010-09-29 艾匹托普技术(布里斯托尔)有限公司 组合物
CN105102477A (zh) * 2013-01-15 2015-11-25 艾匹托普国际股份有限公司 肽
CN105121463A (zh) * 2013-01-15 2015-12-02 艾匹托普国际股份有限公司 肽

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111983241A (zh) * 2020-09-04 2020-11-24 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法

Also Published As

Publication number Publication date
JP2020530846A (ja) 2020-10-29
AU2018316662A1 (en) 2020-02-20
WO2019034862A1 (en) 2019-02-21
EP3668535A1 (en) 2020-06-24
ZA202000882B (en) 2023-08-30
CA3072867A1 (en) 2019-02-21
AU2025201115A1 (en) 2025-03-06
JP7419229B2 (ja) 2024-01-22
US20210093695A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
JP5801197B2 (ja) 痛みの治療に関する薬剤及び方法
Baxter The origin and application of experimental autoimmune encephalomyelitis
AU2025201115A1 (en) Method
JP5361895B2 (ja) 組成物
JP2020500897A (ja) 補体活性のモジュレータ
JP7756968B2 (ja) 嗜癖およびその再発に対する抵抗におけるポリペプチドの使用ならびに複合体およびポリペプチド
TW202034943A (zh) 補體抑制劑之神經疾病治療
JP2018502093A (ja) 組成物
CN110343171A (zh) 周围神经的IgG刺激髓鞘再生
AU2018206356B2 (en) Therapeutic method using tolerogenic peptides
EP4103223A2 (en) Platelet factors and cognitive improvement
US9617325B2 (en) Treatment of IgE-mediated disease
JP2020519627A (ja) 神経保護および再ミエリン化のための可溶性ｃｄ２４の使用方法
KR20240015672A (ko) 면역원성 펩티드를 사용한 개선된 치료 방법
KR20230135556A (ko) 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도
CN107896494A (zh) 多肽组合物
HK40016470B (en) Therapeutic method using dose escalation protocol for tolerogenic peptides
HK40016470A (en) Therapeutic method using dose escalation protocol for tolerogenic peptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230327

Address after: Room 215, Building 2, No. 198, Peninsula Middle Road, Dipu Street, Anji County, Huzhou City, Zhejiang Province

Applicant after: Baimingxinkang Biotechnology (Zhejiang) Co.,Ltd.

Address before: Winter County, England

Applicant before: APITOPE TECHNOLOGY (BRISTOL) Ltd.